drugset / Trial / NCT00282048

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

NCT00282048

Phase 2 Completed 62 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).

Timeline

Start
2006-03
Primary completion
2009-02
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg

Indications